Subscribe: Thursday, 3 December 2009
Preview: Thursday, 3 December 2009

PBR - News

Pharmaceutical Business Review - News

Last Build Date: Wed, 21 Mar 2018 09:05:05 Z


Cipher Pharmaceuticals to acquire Canadian business portfolio of Cardiome Pharma

Wed, 21 Mar 2018 07:23:00 Z

Cipher Pharmaceuticals has entered into a definitive arrangement agreement to acquire the Canadian business portfolio of Cardiome Pharma.

FDA expands approval of Seattle Genetics’ Adcetris for advanced classical Hodgkin Lymphoma

Wed, 21 Mar 2018 06:02:00 Z

Seattle Genetics’ Adcetris (Brentuximab Vedotin) in combination with chemotherapy has been approved by the US Food and Drug Administration (FDA) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL).

Study says non-antibiotic drugs affect gut bacteria

Tue, 20 Mar 2018 10:03:00 Z

Researchers from European Molecular Biology Laboratory (EMBL) have revealed that one in four drugs with human targets could affect the growth of bacteria in the human gut.

Arena’s etrasimod meets primary and secondary endpoints in ulcerative colitis trial

Tue, 20 Mar 2018 08:09:00 Z

Arena Pharmaceuticals has reported positive topline phase 2 results from the OASIS trial for etrasimod, an investigational, once-daily, orally administered, selective sphingosine 1-phosphate (S1P) receptor modulator in development for the treatment of ulcerative colitis (UC).

FDA grants Xtandi priority review for Nonmetastatic CRPC

Tue, 20 Mar 2018 08:02:00 Z

The US Food and Drug Administration (FDA) has accepted Pfizer and Astellas Pharma's supplemental New Drug Application (sNDA) for Xtandi (enzalutamide) for a new indication and granted priority review designation.

Heron’s pain drug succeeds in phase 3 bunionectomy and hernia repair trials

Tue, 20 Mar 2018 06:07:00 Z

Heron Therapeutics’ pain drug HTX-011 has succeeded in two phase 3 trials in patients undergoing bunionectomy and hernia repair by meeting all their primary and key secondary points.

Bavarian Nordic partners with US DoD to develop vaccine for encephalitis virus

Mon, 19 Mar 2018 08:27:00 Z

Bavarian Nordic has entered into a partnership with the US Department of Defense (DoD) for the development of a prophylactic vaccine against the equine encephalitis virus, a rare yet deadly mosquito-borne illness.

FDA approves Hizentra to treat chronic inflammatory demyelinating polyneuropathy

Mon, 19 Mar 2018 07:54:00 Z

The US Food and Drug Administration (FDA) has approved CSL Behring’s Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) as the first and only subcutaneous immunoglobulin (SCIg) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.

Lundbeck to buy Prexton Therapeutics in EUR905m deal

Mon, 19 Mar 2018 05:51:00 Z

Danish pharma company H. Lundbeck has agreed to acquire Switzerland-based Prexton Therapeutics, which develops drugs for Parkinson's disease and other brain disorders, in a deal worth about DKK6.75bn (€905m).

Alexion’s rare blood disorder treatment ALXN121 succeeds in phase 3 study

Fri, 16 Mar 2018 09:31:00 Z

Alexion Pharmaceuticals' investigational long-acting C5 complement inhibitor, ALXN1210, has succeeded in the pivotal phase 3 study of patients with rare blood disorder, paroxysmal nocturnal hemoglobinuria (PNH).

Zymeworks plans to take second drug into trials in HER2-expressing cancers

Fri, 16 Mar 2018 08:28:00 Z

Zymeworks announced that ZW49 is the first product candidate selected for clinical development using the ZymeLink antibody-drug conjugate (ADC) platform, acquired as part of its 2016 purchase of Kairos Therapeutics.

Destiny Pharma's XF-73 MRSA drug gets FDA fast track designation

Fri, 16 Mar 2018 07:41:00 Z

Destiny Pharma’s has secured fast track designation from the US Food and Drug Administration (FDA) for its lead clinical candidate exeporfinium chloride (XF-73) for the prevention of post-surgical staphylococcal infections such as Methicillin Resistant Staphylococcus aureus (MRSA).

Ionis licenses to Akcea global rights to inotersen in $1.7bn deal

Fri, 16 Mar 2018 06:42:00 Z

Ionis Pharmaceuticals has licensed to Akcea Therapeutics worldwide rights to inotersen and AKCEA-TTR-LRx, formerly IONIS-TTR-LRx, in a transaction potentially worth about $1.7bn.

Foghorn Therapeutics raises $50m in funding

Thu, 15 Mar 2018 08:36:00 Z

Flagship Pioneering has made an initial capital commitment of $50m into Foghorn Therapeutics, a developer of therapies for cancer and other serious diseases.

CrownBio selected to advance Phanes Therapeutics' oncology drug pipeline

Thu, 15 Mar 2018 08:24:00 Z

Phanes Therapeutics has selected Crown Bioscience (CrownBio) as a strategic partner to advance its oncology drug discovery pipeline.

Proteostasis' PTI-428 gets FDA orphan drug designation to treat cystic fibrosis

Thu, 15 Mar 2018 07:59:00 Z

Proteostasis Therapeutics has secured orphan drug designation from the US Food and Drug Administration (FDA) for its PTI-428, which is a cystic fibrosis transmembrane conductance regulator (CFTR) amplifier drug candidate.

FDA puts clinical hold on Solid Biosciences' Duchenne gene therapy trial

Thu, 15 Mar 2018 06:15:00 Z

The US Food and Drug Administration (FDA) has placed a clinical hold on Solid Biosciences' IGNITE DMD phase Phase I/II trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD).

AbbVie’s Elagolix succeeds in second phase 3 uterine fibroid study

Wed, 14 Mar 2018 09:17:00 Z

AbbVie, along with Neurocrine Biosciences, announced that the Phase 3 ELARIS UF-II study (M12-817) of elagolix met its primary endpoint.

Kiadis raises €23.4m to develop immunotherapy for GVHD

Wed, 14 Mar 2018 07:26:00 Z

Kiadis Pharma has raised €23.4m of funding in a private placement of 2.6 million new shares, for developing a T-cell immunotherapy product to reduce Graft versus Host Disease (GVHD) in hematopoietic stem cell transplantations (HSCT).

FDA grants priority review to Merck’s Keytruda for cervical cancer

Wed, 14 Mar 2018 05:56:00 Z

Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) has been granted priority review designation by the US Food and Drug Administration (FDA) for the treatment of advanced cervical cancer.